Oxford Biomedica appoints head of manufacturing

Follows acquisition of former RecipharmCobra Biologics manufacturing facility in Oxford, UK

Oxford BioMedica, a UK developer of gene-based medicines and therapeutic vaccines, has appointed James Christie to the newly created role of head of manufacturing. The appointment follows Oxford BioMedica’s recent acquisition of a manufacturing facility based in Oxford, UK from RecipharmCobra Biologics.

Christie, a senior biopharmaceutical executive with more than 30 years of experience in the industry, was most recently operations director at BTG.

He began his career in the biopharmaceutical industry in 1980 and worked at GlaxoSmithKline, Celltech Group and Centocor, before joining Therapeutic Antibodies in 1998. When Therapeutic Antibodies merged with Proteus International in September 1999 to create Protherics, Christie was appointed to the board with responsibility for manufacturing, quality, process development and technical support operations in Australia, the UK and the US.

John Dawson, chief executive of Oxford BioMedica, said: ‘James’s operational and technical leadership will be instrumental as we bring our recently acquired proprietary manufacturing facility into operation during 2012 and seek to implement improved processes at increased scale for late-stage clinical development.’

You may also like

Pharmaceutical

UK vaccine manufacturing nonprofit signs first industry partnership

Oxford Biomedica will be collaborating with VMIC to enable scaled-up manufacture of viral vector-based vaccines
Recruitment

CGT Catapult addresses skills gap with apprenticeship programme for advanced therapies

Programme will address the projected skills shortage facing public and private employers in the growing cell and gene therapy sector
Design & Build

WHP completes bio-manufacturing facility for Oxford BioMedica

Additional cleanroom space took less than 12 months from concept to completion and creates extra capacity
Research & Development

Oxford BioMedica signs LentiVector agreement with GSK

For the development of six product candidates targeting rare orphan diseases
Finance

Oxford BioMedica wins more than £7m in funding to support development of ATMPs

Will develop serum-free, non-adherent manufacturing techniques and expand its plant in Oxford
Research & Development

Oxford BioMedica collaborates with Novartis

Expects to receive between £2.5m and £4m over next 12 months
Research & Development

Oxford BioMedica enters glaucoma agreement

Will collaborate with Mayo Clinic to develop gene therapy for chronic glaucoma
Subscribe now